Trials / Completed
CompletedNCT04276207
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
Effects of LY900014 on Recovery From Hyperglycemia Compared to Humalog in Subjects With Type 1 Diabetes Mellitus (T1DM) on Continuous Subcutaneous Insulin Infusion
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to compare LY900014 to insulin lispro (Humalog) in participants with type 1 diabetes who are using an insulin pump and have high blood sugar after eating. For each participant, the study will last about two to nine weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY900014 | Administered by CSII |
| DRUG | Insulin Lispro | Administered by CSII |
Timeline
- Start date
- 2020-02-25
- Primary completion
- 2020-08-10
- Completion
- 2020-08-10
- First posted
- 2020-02-19
- Last updated
- 2021-08-25
- Results posted
- 2021-08-25
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04276207. Inclusion in this directory is not an endorsement.